<img src="https://ml.globenewswire.com/Resource/Download/6c319974-0bac-45f1-83d9-ae9987dfdf44?size=2" nborder="0" align="left" hspace="5" vspace="5" title="ADPT new logo.jpg" alt="Adaptive Biotechnologies"/>SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2026 after market close on Wednesday, July 29, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: <a href="https://www.globenewswire.com/Tracker?data=IGFd5daylA8FTVOvEk5K7tqzR0DZZ5DTOf-dLaWJ0Kka1szCTV97j0p9Qk2Scqnxoard_r-UQWv-uOc6fjFhbe2ABCvWABxPTmF07lkYA3o=" rel="nofollow" target="_blank" title="www.adaptivebiotech.com">www.adaptivebiotech.com</a>. The webcast will be archived and available for replay within 24 hours after the event. About Adaptive Biotechnologies Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. ADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations and FP&amp;A 201-396-1687 <a href="https://www.globenewswire.com/Tracker?data=KJDfQcuQBRsW7Gz8KwWCohtQxwHcJJ2wCGhtObyofyQmlaeZx6KVRcxWD3o3vrEtLTz4u1zZcMat8eVfrDWlacbGwUOZ_L6trdGngnK4xQeI_rgJNJYctjALKaCJlAfJ" rel="nofollow" target="_blank" title="investors@adaptivebiotech.com">investors@adaptivebiotech.com</a> ADAPTIVE MEDIA Erica Jones, Associate Corporate Communications Director 206-279-2423 <a href="https://www.globenewswire.com/Tracker?data=a4lRpx9h8zj595AFAfkRFuV2U-Fi19WaUXxM0ud_G6mPkuem43hHPHp8BBJxV-_-jf9VY89YDPBzT_cX69vYmD4v1bcSHW3dsJf6sPQLT3juxNNYg1FohHSMjSP0UWbD" rel="nofollow" target="_blank" title="media@adaptivebiotech.com">media@adaptivebiotech.com</a> <img alt="" src='https://ml.globenewswire.com/media/ODljNWQ2N2YtY2Y4OC00NTAzLTg5NDItODBiNzQ5ZDNmNDY3LTExODg3NTItMjAyNi0wNy0wOS1lbg==/tiny/Adaptive-Biotechnologies.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn